Printer Friendly

BRENT LARSEN NAMED DIRECTOR, PROCESS DEVELOPMENT FOR PROTEIN DESIGN LABS

 BRENT LARSEN NAMED DIRECTOR, PROCESS DEVELOPMENT
 FOR PROTEIN DESIGN LABS
 MOUNTAIN VIEW, Calif., June 9 /PRNewswire/ -- Protein Design Labs Inc. (PDL) (NASDAQ: PDLI) announced today that Brent R. Larsen, Ph.D., an expert in biotechnology drug development and quality control, joined the company in May as director, Process Development.
 Larsen, 45, will be responsible for development of purification and testing procedures for PDL's products to meet stringent FDA regulations. "Brent's appointment is an important addition to the management team at PDL. His experience and expertise will be invaluable to our company," said Laurence Jay Korn, Ph.D., president and chief executive officer.
 "I look forward to helping PDL build a first-class product development team so that we can rapidly move additional products from our expanding product portfolio into clinical trials," said Larsen.
 Previously, Larsen was a senior scientist in the QC Research and Development Group, Medicinal and Analytical Chemistry Department for Genentech Inc. which he joined in 1987. At that company, he managed a group to establish test procedures and specifications for all recombinant protein products earmarked for clinical testing. Larsen also spent four years at Monsanto in the mid-80s as a research specialist in the Materials Characterization Group, Bioprocess Development.
 He has also taught at the University of Arizona School of Medicine and the University of Houston. Larsen has published about 20 scientific papers in recent years.
 Protein Design Labs, founded in 1987, is engaged in the computer- based design of antibodies and other novel proteins to treat various disease conditions, including viral infections, autoimmune diseases and cancer. PDL has corporate partnerships and product licensing agreements with four major pharmaceutical companies: Hoffmann-La Roche Inc., Sandoz Pharmaceuticals, Yamanouchi Pharmaceutical Co. Ltd., and Kanebo Ltd.
 The company's initial product-development focus is on SMART Antibodies(TM), which combine the binding sites of a mouse antibody with a large part of a human antibody. PDL's first product, the SMART Anti-Tac Antibody, entered clinical trials in January 1992. It has potential for the treatment of graft-versus-host disease, organ transplant rejection, and certain autoimmune diseases and blood cancers. PDL believes that SMART antibodies, which are designed using the company's proprietary computer modeling techniques, will overcome the limitations of mouse antibodies and will have greatly increased effectiveness in human patients.
 -0- 6/9/92
 /CONTACT: Harold J. Voelkel of Protein Design Labs, 415-903-3700/
 (PDLI) CO: Protein Design Labs ST: California IN: MTC SU: PER


RM-MC -- SJ001 -- 8195 06/09/92 08:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1992
Words:407
Previous Article:CRAY RESEARCH SPONSORS AWARD HONORING PIONEERS USING COMPUTATIONAL SCIENCE
Next Article:SOUTHWESTERN BELL ANNOUNCES LABORATORY TRIAL USING SIEMENS STROMBERG-CARLSON MAN SYSTEM
Topics:


Related Articles
PROTEIN DESIGN LABS HIRES VETERAN BUSINESS JOURNALIST FOR COMMUNICATIONS POST
DEVELOPER OF HUMAN ANTIBODIES JOINS PROTEIN DESIGN LABS
PHARMACEUTICAL EXECUTIVE MAX LINK ELECTED DIRECTOR OF PROTEIN DESIGN LABS
PROTEIN DESIGN LABS REPORTS SECOND QUARTER 1994 FINANCIAL RESULTS
HOFFMANN-LA ROCHE BEGINS PHASE III STUDY OF PDL'S SMART ANTI-TAC ANTIBODY IN KIDNEY TRANSPLANTATION
PROTEIN DESIGN LABS REPORTS SECOND QUARTER 1995 FINANCIAL RESULTS
CIMA LABS NAMES JOHN SIEBERT CHIEF EXECUTIVE OFFICER
PROTEIN DESIGN LABS REPORTS THIRD QUARTER 1995 FINANCIAL RESULTS
PROTEIN DESIGN LABS' ANTI-INFLAMMATORY ANTIBODY IS EFFECTIVE IN PRIMATE STUDY; MILESTONE PAYMENT RECEIVED FROM COLLABORATIVE PARTNER BOEHRINGER...
Brett Schmidli Joins Protein Design Labs as Senior Vice President, Technical Operations.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters